METHODS

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly ed...

Full description

Saved in:
Bibliographic Details
Main Authors HALL, Christopher H, FARR, George William, PELLETIER, Marc F, BORON, Walter F, MCGUIRK, Paul Robert
Format Patent
LanguageEnglish
Published 22.11.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.
AbstractList The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.
Author BORON, Walter F
PELLETIER, Marc F
FARR, George William
HALL, Christopher H
MCGUIRK, Paul Robert
Author_xml – fullname: HALL, Christopher H
– fullname: FARR, George William
– fullname: PELLETIER, Marc F
– fullname: BORON, Walter F
– fullname: MCGUIRK, Paul Robert
BookMark eNrjYmDJy89L5WRg93UN8fB3CeZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGhwUYGhhbGxiYmRiaOhsbEqQIALHgdsg
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US2018334424A1
GroupedDBID EVB
ID FETCH-epo_espacenet_US2018334424A13
IEDL.DBID EVB
IngestDate Fri Nov 08 04:48:02 EST 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US2018334424A13
Notes Application Number: US201815982644
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181122&DB=EPODOC&CC=US&NR=2018334424A1
ParticipantIDs epo_espacenet_US2018334424A1
PublicationCentury 2000
PublicationDate 20181122
PublicationDateYYYYMMDD 2018-11-22
PublicationDate_xml – month: 11
  year: 2018
  text: 20181122
  day: 22
PublicationDecade 2010
PublicationYear 2018
RelatedCompanies Aeromics, Inc
RelatedCompanies_xml – name: Aeromics, Inc
Score 3.1779592
Snippet The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for...
SourceID epo
SourceType Open Access Repository
SubjectTerms ACYCLIC OR CARBOCYCLIC COMPOUNDS
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title METHODS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181122&DB=EPODOC&locale=&CC=US&NR=2018334424A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMTBLTDI3SjTQTUozMtE1MbVIBmYp80TdJAPzpCTTVGCFCz5KydfPzCPUxCvCNIKJIQe2FwZ8Tmg5-HBEYI5KBub3EnB5XYAYxHIBr60s1k_KBArl27uF2LqoQXvHwOrK0MhIzcXJ1jXA38XfWc3Z2TY0WM0vCCwHtNbEyMQR2FdiBTakzUH5wTXMCbQvpQC5UnETZGALAJqXVyLEwJSaJ8zA6Qy7e02YgcMXOuUNZEJzX7EIA7uva4iHv0uwKIOym2uIs4cu0MR4uAfiQ4ORrTcWY2ABdu1TJRgU0pLNk02NElNN0pLNgB05y8RUC7PkRDMTC6PkRAsj41RJBhl8Jknhl5Zm4AJxQTvnjIxkGFhKikpTZYFVaEmSHNjnAOBYccI
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD6MeZlvOpWp8wJK34o1Sy8-FHG9UHVth21lbyUJKQgyh6v49z0Nne5pbyEHziGBL1--JOcE4MawGLcJM3ReEapT0xEIKZvp3LA5NyUSriqlFCdWVNDnmTnrwMcqF0bVCf1RxRERUQLxXqv1evF_iOWrt5XLW_6OXZ8PYe76WquOka7uCNH8sRtMUz_1NM9zi0xLXpUNw1JCH1ErbeEm227wELyNm7yUxTqphPuwPUV_8_oAOnLeh563-nutD7txe-WNzRZ9y0PYiYM8Sv3sCK7DIPciHT2WfwMoi2w9_OgYuijt5QCuKmELkzBJK2GhkLtn0rEEs6hDBHPISJ7AcJOn083mS-hFeTwpJ0_JyxnsNaYmi46QIXTrr295jnRa8ws1C79gFnS1
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=METHODS&rft.inventor=HALL%2C+Christopher+H&rft.inventor=FARR%2C+George+William&rft.inventor=PELLETIER%2C+Marc+F&rft.inventor=BORON%2C+Walter+F&rft.inventor=MCGUIRK%2C+Paul+Robert&rft.date=2018-11-22&rft.externalDBID=A1&rft.externalDocID=US2018334424A1